Ovid Therapeutics Inc [OVID] stock is trading at $1.29, down -3.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OVID shares have gain 2.38% over the last week, with a monthly amount glided 159.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer downgraded its rating to Perform on June 18, 2024. On April 30, 2024, B. Riley Securities initiated with a Buy rating and assigned a price target of $9 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $9 on April 29, 2024. Wedbush initiated its recommendation with a Outperform and recommended $8 as its price target on April 05, 2024. BTIG Research started tracking with a Buy rating for this stock on December 21, 2023, and assigned it a price target of $11. In a note dated October 13, 2023, Oppenheimer initiated an Outperform rating and provided a target price of $8 on this stock.
Ovid Therapeutics Inc [OVID] stock has fluctuated between $0.24 and $1.47 over the past year. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $1.29 at the most recent close of the market. An investor can expect a potential return of 468.22% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Ovid Therapeutics Inc [NASDAQ:OVID] reported sales of 6.65M for the trailing twelve months, which represents a growth of 3611.24%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -6.25%, Pretax Profit Margin comes in at -5.74%, and Net Profit Margin reading is -5.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.59 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2600 points at the first support level, and at 1.2300 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3300, and for the 2nd resistance point, it is at 1.3700.
Ratios To Look Out For
For context, Ovid Therapeutics Inc’s Current Ratio is 4.72. As well, the Quick Ratio is 4.72, while the Cash Ratio is 3.18. Considering the valuation of this stock, the price to sales ratio is 13.79, the price to book ratio is 1.64.
Transactions by insiders
Recent insider trading involved ALEXANDER MARGARET A., President and COO, that happened on Feb 26 ’25 when 5279.0 shares were sold. CBFO, Rona Jeffrey A completed a deal on Feb 26 ’25 to sell 3902.0 shares. Meanwhile, President and COO ALEXANDER MARGARET A. bought 6810.0 shares on Jan 27 ’25.
